Decision Moment: Clinical Hold For Legend's CAR-T Amid Bated Breath Over BCMA Decision
China's Cell Therapy Challenges
Executive Summary
Nanjing-based Chinese biotech says it has had a US clinical hold put in place for it CAR-T, amid broader challenges for China's cell therapy sector and more measured reaction to the setback than the recent immuno-oncology decision in the US.